3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
11
Neoplasm Metastasis
2
HER2 Positive Metastatic Breast Cancer
2
Urinary Bladder Neoplasms
1
Oesophagogastric Cancer
1
Neoplasms
1
Invasive Breast Cancer
1
HER2-positive Advanced Breast Cancer
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Diseases
1
Interventions
Drug Therapy
4
apatinib
3
Oxaliplatin
3
pemigatinib
2
pembrolizumab
2
cemiplimab
2
avelumab
2
atezolizumab
2
S 1 (combination)
2
Nivolumab
2
Leucovorin
2
Irinotecan
2
Folfox protocol
2
Fluorouracil
2
Everolimus
2
Erlotinib Hydrochloride
2
Endoscopic Mucosal Resection
2
Docetaxel
2
Capecitabine
2
CGX1321
2
vandetanib
1
titanium silicide
1
tepotinib
1
tegafur-gimeracil-oteracil
1
talazoparib
1
sodium thiosulfate
1
selpercatinib
1
rucaparib
1
pralsetinib
1
ponatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Gastrointestinal Neoplasms
×
Lapatinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled